Search

The follow-up of external science alerts received from gamma-ray burst (GRB) and gravitational wave detectors is one of the AGILE Team's current major activities. The AGILE team developed an automated real-time analysis pipeline to analyze AGILE Gamma-Ray Imaging Detector (GRID) data to detect possible counterparts in the energy range 0.1–10 GeV. This work presents a new approach for detecting GRBs using a convolutional neural network (CNN) to classify the AGILE-GRID intensity maps by improving the GRB detection capability over the Li & Ma method, currently used by the AGILE team. The CNN is trained with large simulated data sets of intensity maps. The AGILE complex observing pattern due to the so-called "spinning mode" is studied to prepare data sets to test and evaluate the CNN. A GRB emission model is defined from the second Fermi-LAT GRB catalog and convoluted with the AGILE observing pattern. Different p-value distributions are calculated, evaluating, using the CNN, millions of background-only maps simulated by varying the background level. The CNN is then used on real data to analyze the AGILE-GRID data archive, searching for GRB detections using the trigger time and position taken from the Swift-BAT, Fermi-GBM, and Fermi-LAT GRB catalogs. From these catalogs, the CNN detects 21 GRBs with a significance of ≥3σ, while the Li & Ma method detects only two GRBs. The results shown in this work demonstrate that the CNN is more effective in detecting GRBs than the Li & Ma method in this context and can be implemented into the AGILE-GRID real-time analysis pipeline. [ABSTRACT FROM AUTHOR]

In recent years, a new generation of space missions has offered great opportunities for discovery in high-energy astrophysics. In this article we focus on the scientific operations of the Gamma-Ray Imaging Detector (GRID) on board the AGILE space mission. AGILE-GRID, sensitive in the energy range of 30 MeV-30 GeV, has detected many γ-ray transients of both galactic and extragalactic origin. This work presents the AGILE innovative approach to fast γ-ray transient detection, which is a challenging task and a crucial part of the AGILE scientific program. The goals are to describe (1) the AGILE Gamma-Ray Alert System, (2) a new algorithm for blind search identification of transients within a short processing time, (3) the AGILE procedure for γ-ray transient alert management, and (4) the likelihood of ratio tests that are necessary to evaluate the post-trial statistical significance of the results. Special algorithms and an optimized sequence of tasks are necessary to reach our goal. Data are automatically analyzed at every orbital downlink by an alert pipeline operating on different timescales. As proper flux thresholds are exceeded, alerts are automatically generated and sent as SMS messages to cellular telephones, via e-mail, and via push notifications from an application for smartphones and tablets. These alerts are crosschecked with the results of two pipelines, and a manual analysis is performed. Being a small scientific-class mission, AGILE is characterized by optimization of both scientific analysis and ground-segment resources. The system is capable of generating alerts within two to three hours of a data downlink, an unprecedented reaction time in γ-ray astrophysics. [ABSTRACT FROM AUTHOR]

Although several tools facilitating in silico drug design are available, their results are usually difficult to integrate with publicly available information or require further processing to be fully exploited. The rational design of multi-target ligands (polypharmacology) and the repositioning of known drugs towards unmet therapeutic needs (drug repurposing) have raised increasing attention in drug discovery, although they usually require careful planning of tailored drug design strategies. Computational tools and data-driven approaches can help to reveal novel valuable opportunities in these contexts, as they enable to efficiently mine publicly available chemical, biological, clinical, and disease-related data. Based on these premises, we developed LigAdvisor, a data-driven webserver which integrates information reported in DrugBank, Protein Data Bank, UniProt, Clinical Trials and Therapeutic Target Database into an intuitive platform, to facilitate drug discovery tasks as drug repurposing, polypharmacology, target fishing and profiling. As designed, LigAdvisor enables easy integration of similarity estimation results with clinical data, thereby allowing a more efficient exploitation of information in different drug discovery contexts. Users can also develop customizable drug design tasks on their own molecules, by means of ligand- and target-based search modes, and download their results. LigAdvisor is publicly available at https://ligadvisor.unimore.it/., (© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.)

Targeted anticancer therapies represent the most effective pharmacological strategies in terms of clinical responses. In this context, genetic alteration of several oncogenes represents an optimal predictor of response to targeted therapy. Integration of large-scale molecular and pharmacological data from cancer cell lines promises to be effective in the discovery of new genetic markers of drug sensitivity and of clinically relevant anticancer compounds. To define novel pharmacogenomic dependencies in cancer, we created the Mutations and Drugs Portal (MDP, http://mdp.unimore.it), a web accessible database that combines the cell-based NCI60 screening of more than 50,000 compounds with genomic data extracted from the Cancer Cell Line Encyclopedia and the NCI60 DTP projects. MDP can be queried for drugs active in cancer cell lines carrying mutations in specific cancer genes or for genetic markers associated to sensitivity or resistance to a given compound. As proof of performance, we interrogated MDP to identify both known and novel pharmacogenomics associations and unveiled an unpredicted combination of two FDA-approved compounds, namely statins and Dasatinib, as an effective strategy to potently inhibit YAP/TAZ in cancer cells.